Hong Kong University of Science and Technology process allows extraction of Schisandrin B.



MitoPharm signed an exclusive, worldwide licensing agreement with the Hong Kong University of Science and Technology for the use and commercialization of its patent-pending process for the extraction of (-) Schisandrin B and Schisandrin B.


MitoPharm reports that it thus gains the first commercial-scale process for the extraction of Schisandrin B that delivers a high degree of purity and well-defined bacterial levels. The process incorporates hybrid chromatography, which is widely used in the fine chemical and pharmaceutical industries for the recovery of high-purity products.








This site uses Akismet to reduce spam. Learn how your comment data is processed.